Abstract
Interleukin-3 (IL-3) regulates the proliferation, survival and differentiation of haematopoietic cells via interaction with specific cell-surface receptors. IL-3 is expressed in several non-hematopoietic cell types. Studies have demonstrated the presence of IL-3 in the central nervous system, however, its physiological role in these cells is poorly understood. Previously we have been demonstrated that IL-3 prevents neuronal death induced by fibrillary β amyloid in these cells, by PI 3-kinase and Jak/STAT pathway activation. In this study, we demonstrated that IL-3 significantly reduced Aβ- promoted neurite degeneration and toxicity. Thus, this cytokine provides cellular protection against Aβ neurotoxicity in primary cortical neuronal cells, by modulating microtubular dynamics and prevention of tau cleavage and hyperphosphorylation. We also demonstrates that IL-3 is expressed in the “in vivo” mouse model of AD, Tg2576, which also expresses human AβPP with the Swedish mutation. In summary, these results suggest that IL-3 could play a neuroprotective role in AD.
Keywords: IL-3, neuroprotection, Tau, Tg2576, Aβ, neurodegeneration, cytokines, caspase 3.
Current Alzheimer Research
Title: IL-3 Control Tau Modifications and Protects Cortical Neurons from Neurodegeneration
Volume: 7 Issue: 7
Author(s): A. Zambrano, C. Otth, R.B. Maccioni and I.I. Concha
Affiliation:
Keywords: IL-3, neuroprotection, Tau, Tg2576, Aβ, neurodegeneration, cytokines, caspase 3.
Abstract: Interleukin-3 (IL-3) regulates the proliferation, survival and differentiation of haematopoietic cells via interaction with specific cell-surface receptors. IL-3 is expressed in several non-hematopoietic cell types. Studies have demonstrated the presence of IL-3 in the central nervous system, however, its physiological role in these cells is poorly understood. Previously we have been demonstrated that IL-3 prevents neuronal death induced by fibrillary β amyloid in these cells, by PI 3-kinase and Jak/STAT pathway activation. In this study, we demonstrated that IL-3 significantly reduced Aβ- promoted neurite degeneration and toxicity. Thus, this cytokine provides cellular protection against Aβ neurotoxicity in primary cortical neuronal cells, by modulating microtubular dynamics and prevention of tau cleavage and hyperphosphorylation. We also demonstrates that IL-3 is expressed in the “in vivo” mouse model of AD, Tg2576, which also expresses human AβPP with the Swedish mutation. In summary, these results suggest that IL-3 could play a neuroprotective role in AD.
Export Options
About this article
Cite this article as:
Zambrano A., Otth C., Maccioni R.B. and Concha I.I., IL-3 Control Tau Modifications and Protects Cortical Neurons from Neurodegeneration, Current Alzheimer Research 2010; 7 (7) . https://dx.doi.org/10.2174/156720510793499011
DOI https://dx.doi.org/10.2174/156720510793499011 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Monoamine Oxidase-B (MAO-B) Inhibitors in the Treatment of Alzheimer’s and Parkinson’s Disease
Current Medicinal Chemistry Influence of Oxidative Stress on Catalytic and Non-glycolytic Functions of Glyceraldehyde-3-phosphate Dehydrogenase
Current Medicinal Chemistry The Effect of <i>Stachy sieboldii</i> MIQ. Supplementation on Modulating Gut Microflora and Cytokine Expression in Mice
Combinatorial Chemistry & High Throughput Screening PERK-opathies: An Endoplasmic Reticulum Stress Mechanism Underlying Neurodegeneration
Current Alzheimer Research GABAA Receptor Subtype Selective Cognition Enhancers
Current Drug Targets - CNS & Neurological Disorders Chronic Administration of an Aglycosylated Murine Antibody of Ponezumab Does Not Worsen Microhemorrhages in Aged Tg2576 Mice
Current Alzheimer Research Semantic Memory Disorders in Alzheimers Disease: Clues from Semantic Priming Effects
Current Alzheimer Research Fetal Programming of the Human Brain: Is there a Link with Insurgence of Neurodegenerative Disorders in Adulthood?
Current Medicinal Chemistry Obesity and Metabolic Syndrome Affect the Cholinergic Transmission a nd Cognitive Functions
CNS & Neurological Disorders - Drug Targets Cognitive Function and Heart Failure: The Role of the Adrenergic System
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Prevalence of Neuropsychiatric Symptoms in Alzheimers Disease and Vascular Dementia
Current Alzheimer Research Molecular Modelling Approaches to the Design of Acetylcholinesterase Inhibitors: New Challenges for the Treatment of Alzheimers Disease
Current Pharmaceutical Design Risk Factors in Cardiovascular Disease in Systemic Lupus Erythematosus
Current Cardiology Reviews From Stem Cells to Dopamine Neurons: Developmental Biology Meets Neurodegeneration
CNS & Neurological Disorders - Drug Targets The Test Your Memory (TYM) Test Outperforms the MMSE in the Detection of MCI and Dementia
Current Alzheimer Research Brain Inflammation is a Common Feature of HIV-Infected Patients without HIV Encephalitis or Productive Brain Infection
Current HIV Research Anti-TNF Treatment in Rheumatoid Arthritis
Current Pharmaceutical Design Pin1: A New Genetic Link between Alzheimer’s Disease, Cancer and Aging
Current Aging Science Inhibition of Dipeptidyl Peptidase-4 (DPP-4): A Target to Treat Type 2 Diabetes
Current Enzyme Inhibition